Akeso
PulseAugur coverage of Akeso — every cluster mentioning Akeso across labs, papers, and developer communities, ranked by signal.
- 2026-06-01 funding Akeso Bio was among the top net buyers of Southbound Capital, with HK$2.707 billion in net purchases. source
1 day(s) with sentiment data
-
Akeso's Ivonescimab Outperforms AstraZeneca's Imfinzi in Cancer Trial
Chinese biopharmaceutical company Akeso announced that its immunotherapy drug, Ivonescimab, outperformed AstraZeneca's Imfinzi in a Phase 3 trial for biliary tract cancer. This trial, involving 682 patients, is the firs…
-
Chinese funds boost Hong Kong biotech investments amid sector rally
Mainland Chinese investment funds are increasing their stakes in Hong Kong-listed biotechnology companies, attracted by what analysts describe as attractive valuations and relatively low stock prices. E Fund Management …
-
Akeso's lung cancer drug shows 34% reduced death risk in trials
Akeso's lung cancer drug, ivonescimab, has shown significant promise in phase three clinical trials, reducing the risk of death by 34%. The drug demonstrated a notable survival benefit, with 64.7% of patients alive afte…
-
Southbound Capital Buys HK$4.66B, Akeso Bio Leads Net Purchases
Southbound capital saw a net inflow of HK$4.657 billion, with Akeso Bio, Tencent Holdings, and Pop Mart being the top three net buyers. Akeso Bio specifically received a net purchase of HK$2.707 billion. In contrast, Le…